Clinical trials: Intravenous Infusions
Neoplasm Metastasis
A Study of Intravenous XMT-1107 in Patients With Advanced Solid Tumors
XMT-1107 has been shown in nonclinical studies to slow the growth of tumors. These effects may result from blocking the growth of new blood vessels that help the tumors survive.
- Trial name
- XMT-1107 (NCT01011972)
- Testing
- XMT-1107
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- Mersana Therapeutics
Infections, Bacterial
To Evaluate Plasma and Pulmonary Pharmacokinetics of GSK2140944
Antimicrobial penetration can be assessed through evaluation of antimicrobial concentrations in various lung compartments, including bronchial mucosal tissue, epithelial lining fluid (ELF), and alveolar macrophages (AM).
- Trial name
- NCT01934205
- Testing
- GSK2140944 (Single dose), GSK2140944 (Multiple dose)
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pharmacokinetics of ASP2408, Healthy Subjects
A Study to Evaluate a Single Intravenous (IV) Dose Using a New Manufactured Clone and Single Ascending Doses of Subcutaneous (SC) Injections
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics (PK) after intravenous (IV) administration of ASP2408 manufactured from a new production clone and also following single ascending doses of…
- Trial name
- NCT02150070
- Testing
- ASP2408
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Global Development, Inc.
Obstructive Sleep Apnea
Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Experiencing Excessive Daytime Sleepiness (EDS) Despite Adequate Use of Continuous Positive Airway Pressure (CPAP)
The purpose of this study is to evaluate the safety and tolerability of administering a single intravenous (IV) infusion dose of TAK-925 to adults with obstructive sleep apnea (OSA) who are experiencing excessive daytime…
- Trial name
- NCT04091425
- Testing
- TAK-925
- Where
- 18 sites in United States
- Volunteers
- 25 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Parkinson's Disease
Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease
This multiple ascending dose study is to determine safety, tolerability, pharmacokinetics and immunogenicity of PRX002 in approximately 60 patients with Parkinson's disease.
- Trial name
- NCT02157714
- Testing
- PRX002
- Where
- 8 sites in United States
- Volunteers
- 64 people
- Sponsor
- Prothena Biosciences Limited
Healthy
Pharmacodynamics Study of Enoxalow Compared to Clexane in Healthy Subjects After Intravenous Administration
The hypothesis of this trial is that the test drug (Enoxalow® - T) pharmacodynamics parameters are similar to the comparator drug (Clexane® - C) in healthy subjects following administration of single intravenous dose.
- Trial name
- NCT01692171
- Testing
- Heparin, Low-Molecular-Weight
- Where
- Brazil
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Azidus Brasil
Colorectal Neoplasm, Digestive System Neoplasm
Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors.
This study will include two parts: In the phase I part: safety will be assessed in consecutive cohorts of 3 to 6 patients at increasing doses of TG6002 in combination with oral flucytosine (5-FC) in patients with advanced…
- Trial name
- NCT03724071
- Testing
- TG6002, Flucytosine (5-FC, Ancotil)
- Where
- 7 sites in Belgium, France and 1 more
- Volunteers
- 51 people
- Sponsor
- Transgene
Parkinson's Disease
Single Ascending Dose Study of PRX002 in Healthy Subjects
This single ascending dose study is to determine safety, tolerability, pharmacokinetics and immunogenicity of PRX002 in approximately 40 healthy subjects.
- Trial name
- NCT02095171
- Testing
- PRX002
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Prothena Biosciences Limited
Covid19
Intravenous Infusion of CAP-1002 in Patients With COVID-19
This is a randomized, double-blind, placebo-controlled, Pilot, Phase 2 Exploratory study that will enroll subjects with a clinical diagnosis of COVID-19 confirmed by laboratory testing and who are in severe or critical condition…
- Trial name
- INSPIRE (NCT04623671)
- Testing
- CAP-1002
- Where
- 4 sites in United States
- Volunteers
- 55 people
- Sponsor
- Capricor Inc.
Solid Tumors, High Grade Gliomas
Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection
Study aimed to assess the reproducibility of PET imaging using AH111585 (18F) Injection. Subjects are evaluable if they undergo 2 administrations of AH111585 (18F) Injection (3 to 8 days apart) and the corresponding PET…
- Conditions
- Solid Tumors, High Grade Gliomas, Lung Cancer, Head and Neck Cancer
- Trial name
- NCT00918281
- Testing
- Fluciclatide Injection
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- GE Healthcare
Healthy Volunteer
A Study to Evaluate Adverse Events, How the Drug is Tolerated, and How the Drug Moves Through the Body of Intravenous Infusions of ABBV-8736 in Adult Healthy Volunteers
The objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity following multiple intravenous (IV) ascending doses of ABBV-8736 in healthy adult participants.
- Trial name
- NCT07141199
- Testing
- ABBV-8736
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AbbVie
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as Intravenous (IV) Infusion in Children and Young Adults With Acute Lymphoblastic Leukemia (ALL) /Lymphoblastic Lymphoma (LBL). Following Hypersensitivity to Pegaspargase (Oncaspar)
The purpose of this study is to evaluate the effectiveness,safety, and dosage of pegcrisantaspase in patients with Acute Lymphoblastic Leukemia (ALL) / Lymphoblastic Lymphoma (LBL).
- Trial name
- NCT02257684
- Testing
- pegcrisantaspase
- Where
- 43 sites in United States
- Volunteers
- 4 people
- Sponsor
- Jazz Pharmaceuticals
Total Hip Replacement
Effectiveness of Patient-Controlled Intravenous Analgesia (PCIA) With Fentanyl
To enhance post-operative pain management, patient-controlled intravenous analgesia (PCIA) has been employed. The fentanyl background PCIA therapy was created to solve the limitations of IV-based PCIA, such as programming errors…
- Trial name
- NCT05429567
- Testing
- Fentanyl
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Egymedicalpedia
Portal Hypertension
A Study to Investigate the Safety and Effect of the Study Drug (FE 204205) in Patients With Cirrhotic Portal Hypertension
The purpose of this trial is to investigate safety, tolerability, pharmacodynamics (PD), and pharmacokinetics (PK) after intravenous (IV) administration of FE 204205 in patients with cirrhotic portal hypertension.
- Trial name
- NCT02929407
- Testing
- FE 204205
- Where
- Spain
- Volunteers
- 4 people
- Sponsor
- Ferring Pharmaceuticals
Non-colorectal Cancer, Pancreatic Cancer
Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242 in Treating Patients With Solid Tumors
RATIONALE: Monoclonal antibodies, such as maytansinoid DM4-conjugated humanized monoclonal antibody huC242, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00352131
- Testing
- HuC242-DM4
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- ImmunoGen, Inc.
Anemia, Non-Myeloid Malignancies
Chemotherapy Related Anemia
This study is investigating darbepoetin alfa for the treatment of anemia in patients with non-myeloid cancers who are receiving chemotherapy.
- Trial name
- NCT00035607
- Testing
- Darbepoetin alfa SC, Darbepoetin alfa IV
- Volunteers
- 120 people
- Sponsor
- Amgen
Autoimmune Disease
A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of TAK-079 in Healthy Participants
The purpose of this study is to characterize the pharmacokinetic and safety and tolerability profile of TAK-079 following a single intravenous (IV) infusion or subcutaneous (SC) administration at escalating dose levels in healthy…
- Trial name
- NCT02219256
- Testing
- TAK-079
- Where
- 2 sites in United Kingdom
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Takeda
Heart Failure
Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)
The primary objective of the study is to evaluate the effect of 48 hours of intravenous (IV) omecamtiv mecarbil compared with placebo on dyspnea in subjects with left ventricular systolic dysfunction hospitalized for acute heart…
- Trial name
- NCT01300013
- Testing
- Omecamtiv mecarbil
- Where
- 150 sites in United States, Australia and 17 more
- Volunteers
- 614 people
- Sponsor
- Cytokinetics
Solid Tumors
Safety Study of OXi4503 (a Vascular Disrupting Agent) Given by 3 x Weekly Intravenous Infusions to Patients With Advanced Solid Tumors
The purpose of this study is to establish the Maximum Tolerated Dose (MTD) of OXi4503 given by weekly infusions to patients with advanced solid tumors.
- Trial name
- NCT00977210
- Testing
- OXi4503
- Where
- 2 sites in United Kingdom
- Volunteers
- 40 people
- Sponsor
- Mateon Therapeutics
Stroke
Safety and Tolerability of BIII 890 in Patients With Acute Ischemic Stroke
The objective of this study is to assess the safety, tolerability and pharmacokinetic characteristics of BIII 890 after intravenous infusion in acute ischemic stroke patients.
- Trial name
- NCT02251197
- Testing
- BIII 890 CL
- Volunteers
- 97 people
- Sponsor
- Boehringer Ingelheim